Danny Wells is a scientific co-founder at Immunai and currently serves as the Senior Vice President of Strategic Research. Danny joined the founding team of Immunai during his time as an investigator at the Parker Institute for Cancer Immunotherapy, where he was the founding principal data scientist and led research efforts in genomics and reverse translational medicine. Danny has co-authored dozens of research articles around the intersection of (single-cell) genomics and cancer immunotherapy that have collectively been cited thousands of times, including papers published in Nature, Cell, and Nature Medicine. Before joining the Parker Institute, Danny completed a postdoctoral fellowship in evolutionary biology at the University of California, Berkeley, his PhD in Computational Biology and Applied Mathematics at Northwestern University, where he was an NSF Graduate Research Fellow, and a BA in Mathematics from Carleton College where received the Galovich Prize for accomplishment in undergraduate mathematics research.
Sanjeev Mariathasan leads the biomarker strategy for the Atezolizumab/Tecentriq franchise. He also co-leads the Oncology Reverse Translation group. The aim of this group is to derive mechanistic and therapeutically actionable insights from Roche’s extensive clinical database as well as to identify novel targets for the cancer immunotherapy pipeline. Examples of his research include (1) the revelation of TGFβ-mediated signaling in aiding exclusion of T cells in stromal tissues surrounding the tumors and the demonstration of reversing these effects leading to enhanced anti-tumor efficacy with anti-TGFβ and anti-PD-L1 mAb combination therapy in preclinical models (Mariathasan et al, Nature 2018); and (2) the use of ctDNA as an exploratory endpoint in a phase 3 adjuvant bladder cancer trial, the results of which have the potential to change treatment decision paradigms in early-stage bladder cancer and potentially other solid tumor types (Powles et al, Nature 2021).
Peripheral Biomarkers Guiding Cancer Immunotherapy
Lacey leads the Informatics team, which focuses on using integrated multi-omic data analysis to uncover biomarkers, mechanisms of action, and novel therapies from cancer immunotherapy patient data. Lacey's team specializes in interrogating datasets with small N, large P (many data points, few patients). At the Parker Institute, Lacey has also led the development of a best-in-class data platform to store, integrate, and analyze data from 20+ molecular data types with detailed clinical outcomes and annotation. Before joining the Parker Institute, Lacey worked in various roles in industry and academia, creating novel methods and platforms to analyze biological and patient data. She has a PhD from Stanford University, where she developed algorithms for analyzing brain imaging data, and did her bachelors work and cognitive science and AI research at MIT.
Cancer Immunotherapy Biomarkers from Multi-Omic Data
Lessons in finding biomarkers of response and resistance to cancer immunotherapy using multi-omic data, including DNA sequencing, RNA sequencing, high-dimensional flow cytometry, mass cytometry (CyTOF), proteomics. Discussion of data platforms to store, organize, and analyze multi-omic data. Insights and applications in chemoimmunotherapy for patients with Pancreatic Cancer.
Klaus Lindpaintner, MD, MPH, FACP, Chief Scientific and Medical Officer at InterVenn Biosciences, previously held senior positions at Pfizer as Sr. VP and Global Head, Human Genetics and Computational Biomedicine, at Hoffman-La Roche, as Distinguished Scientist and Global Head, Roche Center for Medical Genomics, spearheading the company’s efforts in personalized health care; as CSO at Thermo-Fisher-Scientific; and on the faculty of Harvard Medical School. Klaus has co-authored some 250 scientific papers, and holds honorary and adjunct professorships at several academic institutions. He serves on numerous boards, working groups, and advisory panels for trade organizations, regulatory authorities, and non-governmental organizations on issues related to the successful implementation and leverage of novel technologies in health care. Klaus graduated from Innsbruck University Medical School with a degree in medicine, and from Harvard University with a degree in public health. He pursued post-graduate training and specialization in internal medicine, cardiology, and clinical and molecular genetics in the US and Germany and is a Diplomate of the Boards in these specialties.
Clinical Dx Showcase:
InterVenn has developed a unique technology platform that combines high resolution mass spectrometry with high throughput artificial-intelligence powered data processing, allowing interrogation of the human glycoproteome at clinical study scale.
Glycoproteomic Profiling: Powerful Predictor of Immunotherapy Response
Using InterVenn's platform we have been able to demonstrate that serum glycoprotein profiles are powerful predictors of likely response or non-response to checkpoint inhibitors, clearly superior to currently available biomarkers across a range of indications and drug molecules.